<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

AZD0156

Cancer    DNA    Irinotecan    AZD0156

Irinotecan breaks cancer cell DNA – AZD0156 keeps the body from repairing it

The chemotherapy drug irinotecan creates DNA damage leading to cell death and is used to treat colorectal cancer, among other cancer types. Now a University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 suggests a way to make irinotecan work even better: When researchers added the experimental drug AZD0156 to irinotecan, colorectal cancer cells and models of human colorectal cancer tumors grown in mice both showed significantly more cancer cell inhibition than with irinotecan used alone. An ongoing phase 1 clinical trial is currently testing the combination against advanced solid tumors (NCT02588105).


Author Cancer Center | Publish Date April 03, 2019
Full Story

CU Cancer Center In the News

The Conversation

Lung cancer is the deadliest of all cancers, and screening could save many lives − if more people could access it

news outletThe Conversation
Publish DateMay 13, 2024

Despite being the leading cause of cancer-related death worldwide, Nina Thomas, MD, shares that lung cancer has a significantly lower screening rate compared to other common cancers. Various barriers, including lack of awareness, misconceptions, geographic and socioeconomic disparities, and stigma surrounding smoking, contribute to this low rate. Lung cancer screening, recommended for high-risk individuals, involves a low-dose CT scan that is quick, non-invasive, and effective in detecting early-stage cancer. Efforts to improve screening rates focus on public education, reducing disparities, and destigmatizing lung cancer and smoking.

Full Story
OncLive

Bradley Corr, MD, on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer

news outletOncLive
Publish DateMay 10, 2024

Bradley R. Corr, MD, explores the rationale and results of a phase 2 trial comparing rucaparib to placebo as maintenance therapy for metastatic and recurrent endometrial cancer. Discover the significant progression-free survival improvements and implications for patients in this insightful discussion.

Full Story
The Colorado Sun

The lucky ones: Former world champion’s life was saved by a clinical trial. Now she wants others to get the chance.

news outletThe Colorado Sun
Publish DateApril 26, 2024

Siri Lindley, a former world champion triathlete, faced her toughest challenge when diagnosed with a rare, aggressive leukemia. Visualizing her favorite mountain trail helped her endure the grueling treatment. She approached cancer like a triathlon, with determination and hope, eventually lobbying for improved access to medical trials. Thanks to a groundbreaking trial at the University of Colorado Cancer Center, she's now cancer-free, living a new life filled with gratitude and a renewed love for sports.

Full Story
Medical Xpress

Writing to wellness: New therapy helps cancer patients face biggest fears

news outletMedical Xpress
Publish DateApril 22, 2024

CU Cancer Center Member Joanna Arch developed EASE therapy for late-stage cancer patients, based on written exposure therapy, to address their unique fears and anxieties. Participants write about their greatest cancer-related fears and explore coping strategies. Results show significant improvements in mental health and well-being.

Full Story